PAMELA TATHAM: Open Payments
NPI 1578220554 · GAFFNEY, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$868 in 33 payments from 13 companies in 2025. Trend: 2023 $900 · 2024 $806 · 2025 $868
Food & beverage: $868
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 7 | $286 |
| AstraZeneca Pharmaceuticals LP | 2 | $109 |
| ABBVIE INC. | 3 | $65 |
| Exact Sciences Corporation | 3 | $55 |
| Vanda Pharmaceuticals Inc. | 3 | $49 |
| Neurocrine BioSciences, Inc. | 2 | $49 |
| Novo Nordisk Inc | 3 | $48 |
| Axsome Therapeutics, Inc. | 2 | $46 |
| Gilead Sciences, Inc. | 2 | $43 |
| Indivior Inc. | 2 | $42 |
Products named: OTEZLA, AIRSUPRA, HETLIOZ, INGREZZA, Auvelity, SUBLOCADE, BRIXADI, VRAYLAR.
Industry payments across SC — which companies pay providers there.
